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ABSTRACT 
 
Background 
Several relatively large studies have assessed molecular indicators of colorectal cancer (CRC) 
prognosis, but most analyses have been restricted to a handful of markers.  
 
Methods 
In stage II/III CRCs from the QUASAR2 clinical trial and from an Australian community-based 
series, we assessed gene panels for somatic driver mutations and overall mutation burden. 
We determined molecular pathways of tumorigenesis, and analysed associations with 
treatment response and prognosis.  
 
Findings 
In QUASAR2 (N=511), TP53, KRAS, BRAF and GNAS mutations were independently associated 
with shorter relapse-free survival, whereas total somatic mutation burden was associated 
with longer survival, even after excluding mismatch repair-deficient (MSI+) and POLE-mutant 
tumours. We successfully validated these associations in the Australian sample set (N=296). 
In an extended analysis of 1,752 QUASAR2 and Australian CRCs for which KRAS, BRAF and MSI 
status was available, we found that KRAS and BRAF mutations were specifically associated 
with poor prognosis in MSI- cancers. This association was not present in MSI+ cancers, and 
MSI+ tumours with KRAS or BRAF mutation actually had better prognosis than MSI- cancers 
that were wildtype for KRAS or BRAF. New rare molecular pathways were also uncovered: 
mutations in the genes NF1 and NRAS from the MAP kinase pathway co-occurred, mutations 
in TP53 and ATM appeared to be alternative ways of inactivating the DNA damage response 
pathway. 
 
Interpretation 
A multi-gene panel has identified two previously unreported prognostic associations in CRC 
involving both TP53 mutation and total mutation burden, and confirmed associations with 
KRAS and BRAF. We conclude that even a modest-sized gene panel can provide important 
information for use in clinical practice and out-perform MSI-based models.  
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INTRODUCTION 
 
It is increasingly recognised that treatment of the common cancers can be modified according 
to a patient’s expected prognosis and/or response to therapy. For some of the newer 
molecularly guided therapies, there exist powerful biomarkers of response, often comprising 
mutations in the specific protein that is targeted. For more conventional cytotoxic therapies, 
however, predictive markers of response are rare. Given the relatively small survival benefits 
that such therapies provide for patients with the common solid malignancies, biomarkers of 
prognosis still have considerable potential clinical importance. Such markers can guide the 
use of more or less aggressive treatment regimens, balancing expected outcome against early 
and late therapeutic toxicities. 
 
Biomarkers can be based on several different types of molecules, and recent high-profile work 
has highlighted the potential utility of mRNA profiling in identifying groups of colorectal 
cancers (CRCs) with varying prognosis1. Other biomarkers are based on DNA, which is 
generally easier to analyse given its stability. For CRCs treated with curative intent, the 
biomarker most consistently used in clinical practice is microsatellite instability (MSI), which 
usually results from defective DNA mismatch repair2. For stage II CRCs , MSI predicts relatively 
good survival, with hazard ratios as low as 0·63. The association is less strong for stage III and 
in stage IV MSI+ CRCs may actually have a relatively poor prognosis4. 
 
Recently, the availability of a few large datasets (>500 participants) from clinical trials has 
begun to clarify the associations of certain somatic mutations with CRC prognosis However, 
most of these analyses have been restricted to KRAS mutations, and/or BRAF mutations 
and/or MSI; their results are summarised in Supp. Table 1. Overall, for CRCs treated with 
curative intent (generally stage II or III), there is support for an association between MSI and 
good prognosis, albeit possibly weaker in stage III, coupled with more limited evidence that 
KRAS and BRAF mutation, which are mutually exclusive, indicate poor prognosis in MSI- 
tumours5-10. MSI+ CRCs tend, however, to be BRAF-mutant and KRAS-wildtype so statistical 
interactions may exist between these prognostic biomarkers. It is, moreover, currently 
unclear whether combinations of other genetic biomarkers provide useful prognostic 
information. 
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Two main reasons have limited large genetic biomarker studies to screening a small number 
of genes: sub-optimal sample quality or quantity; and the cost of mutation screening. Clearly, 
because somatic mutations tend to co-occur in molecular pathways of tumorigenesis, it would 
be highly desirable to screen many potentially prognostic mutations in the same data set and 
identify the primary determinants of tumour behaviour. However, the few studies to perform 
such analyses have lacked standardised recruitment and follow-up. The prime example is the 
exome or genome sequencing of over 600 CRCs by The Cancer Genome Atlas (TCGA) group11. 
This has provided an excellent data set for driver mutation discovery, but has limited use for 
biomarker discovery owing to the heterogeneous sample set and associated variability in the 
clinical data. 
 
Our strategy in this exploratory study was to retain the advantages of a large clinical trial data 
set whilst assessing multiple prognostic biomarkers for CRC. To this end, we used a 82 gene 
panel to identify somatic mutations in all the major CRC driver genes in more than 500 
tumours from the QUASAR2 clinical trial of stage II/III CRC. We also assessed MSI and the 
“ultramutator” phenotype from POLE mutations12. A larger QUASAR2 sample set was 
additionally tested for KRAS/BRAF mutations and MSI. Variables associated with survival in 
QUASAR2 were replication tested in an independent community-based cohort, and subjected 
to a combined analysis, resulting in the identification of four independent prognostic 
biomarkers: mutations in KRAS, BRAF, TP53 and mutation burden.  
 
 
MATERIALS AND METHODS 
 
QUASAR2 was an international clinical trial comprising 1,952 patients with high-risk stage II 
or stage III CRC, randomised to capecitabine +/- bevacizumab without radiotherapy and 
median follow-up of 4.92 years13. Patients in the bevacizumab arm showed no benefit in 
overall or disease-free survival at three years follow-up; comparable results have also been 
reported in two similar trials14,15. Clinico-pathological data (Supp. Table 2) were obtained from 
the trial database. Some were converted to binary variables: sex; location (proximal vs distal); 
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depth of invasion (T4 vs T1/T2/T3); and lymph node metastasis (N2/N1 vs N0). Age and grade 
were assessed as continuous variables.  
 
A total of 1,187 UK QUASAR2 CRCs was collected for molecular analysis, of which a subset of 
598 tumours was analysed using an Ion Torrent sequencing gene panel (Supp. Table 3a). The 
remaining CRCs were analysed by Sanger sequencing for selected mutations and for MSI 
(Supp. Materials and Methods). 40um scrolls were cut from FFPE specimens of CRC that had 
>80% estimated purity, and from normal bowel; 10um sections were cut from the remaining 
CRCs and needle-microdissected to enrich for tumour using a haematoxylin and eosin (H&E) 
section as a guide. Peripheral blood samples were also available from most patients. DNA was 
extracted from FFPE tissue with the DNeasy kit (Qiagen) and from blood with the Maxwell 16 
Blood DNA Purification kit (Promega).  
 
The community-based series comprised 657 patients with stage II or III CRC treated at the 
Royal Melbourne Hospital, Western Hospital Footscray or St Vincent’s Hospital, Sydney, 
Australia since 1993 (Supp. Table 2). Fresh-frozen tumour and matched normal specimens 
were retrieved from hospital tissue banks. Individuals with hereditary CRC syndromes were 
excluded. All patients received standard neo-adjuvant or adjuvant 5FU-based chemotherapy 
or concurrent chemoradiotherapy. 379 patients received adjuvant 5FU treatment, of whom 
47 also received oxaliplatin and 38 had no data on oxaliplatin use. All patients were 
prospectively followed according to standard protocols, with a median follow-up of 60 
months. All patients gave informed consent, and the study was approved by the medical 
ethics committees of all sites. Australian stage II patients were regarded as low-risk when they 
were T3/N0, otherwise as high-risk. A subset of 296 tumours was screened by targeted next-
generation sequencing, the others by conventional PCR-based sequencing (Supp. Table 3b).  
 
Individual driver gene mutations, combinations of mutations or global measures such as MSI 
or mutation burden (total number of non-synonymous mutations and coding indels) were 
tested for associations with relapse-free survival (RFS) in univariable and multivariable 
models, principally using Cox proportional hazards models, in accordance with published 
guidelines16 (Supp. Table 4). Further details of patients and analytical methods are provided 
in Supp. Materials and Methods and Supp. Figure 1. 
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RESULTS 
 
QUASAR2 mutation profiling using a custom gene panel 
 
598 QUASAR2 tumours were sequenced for 82 genes by Ion Torrent technology. We 
eliminated mutations with a high probability of being artefacts and cancers with high levels 
of artefactual hypermutation owing to ex vivo cytosine deamination (Supp. Figures 2-5, Supp. 
Tables 6-9). 511 tumours remained for further analysis (Supp. Figure 1). 
 
We identified all likely driver mutations (see Materials and Methods; Supp. Table 9) and 
selected the 13 most commonly mutated genes (mutated in ≥8 tumours) for further analysis 
to identify mutations tending to occur together in genetic pathways (Supp. Tables 10, 11; 
Supp. Figure 6). In addition to known associations, new findings included a negative 
association between TP53 and GNAS, and a positive association of NF1 with PTEN and NRAS. 
 
Since several mutations co-varied, we searched for primary associations by multivariable 
regression (Supp. Table 13), hierarchical clustering and Bayesian networks (Supp. Figures 7, 
8). Interestingly, all three analytical methods found that mutations in NF1, a gene involved in 
the pathogenesis of neuromas and a negative regulator of the Ras pathway, were positively 
associated with NRAS mutations, but not with mutations in KRAS or BRAF. SMAD4 mutations 
were associated with BRAF mutations, but not with KRAS or NRAS changes, suggesting 
possible synergy between BRAF and the TGFβ or BMP pathways. In addition, logistic 
regression and Bayesian network analyses showed a strong negative association between 
driver mutations in TP53 and ATM, two key mediators in the DNA damage response (DDR) , 
suggesting that these mutations were alternatives DDR inactivators. Finally, clustering and 
Bayesian network analysis suggested a positive association between ATM and PTEN 
mutations. It has recently been shown than PTEN is phosphorylated by ATM in response to 
DNA-damaging agents, thus inducing autophagy17. Regression analysis between molecular 
and clinical variables showed that KRAS mutations were associated with female sex, similarly 
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to BRAF mutations11,18. In addition, mutations in FBXW7 and CTNNB1 were associated with 
high grade, the latter suggesting that activation of the Wnt pathway through beta-catenin 
rather than APC mutation might predispose to poorly differentiated CRCs.  
 
Sub-clonal mutations may be clinically important, for example by driving drug resistance, but 
can be difficult to identify. Our high depth sequencing allowed us to identify 58 tumours (11%) 
carrying somatic mutations at significantly reduced allele frequency, suggesting sub-clonal 
status (see Materials and Methods). Of the 13 most commonly mutated genes, PIK3CA, ATM 
and SMAD4 had lower driver mutation allele frequencies than the other genes (P=0·001, 
0·002 and 0·05 respectively), suggesting they were more often sub-clonal (Supp. Table 14).  
 
Mutation burden, clonal diversity (presence of any identified mutation at low allele 
frequency) and driver mutations in the 13 genes were tested for prediction of bevacizumab 
treatment response, with no significant associations found (data not shown). 
 
 
Markers of prognosis in gene panel analysis of QUASAR2 and the community cohort 
 
In QUASAR2, overall mutation burden and mutations in 4 specific genes (TP53, KRAS, BRAF 
and GNAS) showed promising individual associations with relapse-free survival (RFS) (pre-
defined P<0·10) and were therefore selected for multivariable analysis, together with T stage, 
N stage, treatment arm (as bevacizumab had previously been associated with poorer 
prognosis in the analysis of our patent sub-group although not the whole trial), and MSI (as it 
co-varied with mutation burden and is probably the best established prognostic factor for 
CRC) (Table 1a; Supp. Tables 15, 16). We found mutation burden (HR=0·81; 95%CI=0·68-0·96; 
P=0·014), mutations in TP53, KRAS, BRAF and GNAS, T/N stage and use of bevacizumab were 
all independently associated with poor prognosis (P<0·05), but MSI was not (HR=1·12; 
95%CI=0·57-2·19; P=0·75) (Table 1a). To test whether the prognostic effect of mutation 
burden was only due to hypermutation, the same model was run in the sub-set of tumours 
without MSI or pathogenic POLE mutations. Mutation burden retained a borderline significant 
association with outcome (HR=0·85, 95%CI=0·73-1·00, P=0·051), with the other variables 
showing results similar to those previously found (Table 1a).  
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To replication test our prognostic markers, we used an independent data set from an 
Australian community-based cohort of stage II and III CRC patients (N=296) (Supp. Table 2; 
Supp. Figures 9, 10) in which all prognostic markers identified in QUASAR2, except GNAS 
mutations, had been assessed (see Materials and Methods). A multivariable analysis 
incorporating the same clinical and molecular variables and co-variables showed that, in 
agreement with the QUASAR2 analysis, BRAF mutation, TP53 mutation, and mutation burden 
were associated (P<0·05) with RFS, whereas MSI was not (Table 1b). KRAS mutation also 
showed a similar prognostic association in the Australian patients to that present in QUASAR2, 
although formal significance was not reached. Exclusion of MSI+ and ultramutator tumours 
from the Australian analysis made little difference to the associations, although KRAS became 
formally associated with prognosis and BRAF mutation lost that status (Table 1b).  
 
A combined analysis of the QUASAR2 and Australian cohorts confirmed that mutations in 
KRAS, BRAF and TP53, together with lower mutation burden, were all independently 
associated with poor prognosis, whereas MSI was not (Figure 1; Table 1c; Supp. Table 17).  
Exclusion of MSI+ and ultramutator cancers did not alter our findings. There was no significant 
heterogeneity between cohorts and our model persisted in Australian patients treated with 
chemotherapy (details not shown).  
 
We compared a prognostic model based on the current gold standard of clinico-pathological 
variables and MSI with our new model incorporating clinical variables, mutation burden and 
driver mutations in KRAS, BRAF and TP53. In both QUASAR2 and the Australian cohort, the 
new model performed significantly better (P=4x10-5 and P=0·0057 respectively, likelihood 
ratio test). A 10% leave-out cross-validation analysis showed these analyses to be robust (see 
Supp. Material and Methods).  
 
We then explored the prognostic model separately in stage II (N=266) and stage III (N=499). 
The model was only formally significant (P=7.3x10-8) in the latter case (Supp. Table 18), but 
hazard ratios were very similar in both stages, suggesting the lack of formal significance was 
the result of lower power in the smaller stage II set. Correspondingly, despite inherently 
reduced power, an analysis by tumour location (proximal colon, distal colon, rectum) showed 
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similar hazard ratios for all biomarkers across sites, even after exclusion of hypermutated 
tumours (Supp. Table 19). In addition, formal assessment of interactions between individual 
biomarkers and stage or tumour location found no evidence of significant deviation from a 
log-additive model (details not shown). 
 
 
Patient outcome in relation to combinations of MSI, KRAS and BRAF status in enlarged cohorts 
 
Based on previous reports5-10, we investigated the prognostic associations of KRAS and BRAF 
mutations in relation to MSI status. We pooled data from the QUASAR2 gene panel, the 
Australian validation set, and an additional 676 QUASAR2 and 362 stage II/III Australian CRCs 
that had been analysed for MSI and by Sanger sequencing for KRAS/BRAF mutations (Supp. 
Table 2) for an extended set of 1,732 patients. In a multivariable analysis we found MSI was 
associated with good prognosis (HR=0·45, 95%CI=0·31-0·64, P=1x10-5), and KRAS and BRAF 
mutations were both associated with poor prognosis (HR=1·22, 95%CI=1·01-1·48, P=0·035; 
HR=1·53, 95%CI=1·14-2·04, P=0·004 respectively; Supp. Table 20). Since the strong co-
variation of these biomarkers could potentially have confounded or obscured prognostic 
effects, we added to the multivariable model multiplicative interaction terms between MSI 
and mutations in KRAS and BRAF. We found both of these interactions to be significant 
(P=0·003 and P=0·023 respectively) suggesting differential prognostic effects.  
 
Accordingly, we explored different combinations of MSI, KRAS mutation and BRAF mutation. 
Compared with “triple negative” (MSI-, KRAS-wildtype, BRAF wildtype) cancers, MSI- tumours 
with KRAS or BRAF mutations had a worse prognosis (respectively HR=1·35, 95%CI=1·11-1·64, 
P=0·003 and HR=2·02, 95%CI=1·47-2·77, P=1·19x10-5; Table 2, Figure 2). By contrast, and 
explaining the statistical interactions detected, MSI+ CRCs with KRAS or BRAF mutation had a 
significantly better prognosis than the triple negatives (respectively HR=0·28, 95%CI=0·09-
0·89, P=0·03 and HR=0·55, 95%CI=0·34-0·90, P=0·017; Table 2), although the difference was 
not significant compared with MSI+ CRCs without KRAS/BRAF mutation.  The 6 
MSI/KRAS/BRAF sub-groups showed consistent effects between the QUASAR2 and Australian 
cohorts (details not shown). 
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TP53-based prognostic sub-sets in MSI- CRCs  
 
Although MSI was not an independent prognostic marker when mutation burden was also 
assessed, it was prognostic in the absence of that information (Supp. Table 20). We therefore 
explored whether new prognostic groups within the larger MSI- subset could be identified 
using KRAS, BRAF and TP53, given that TP53 mutation remained an independent prognostic 
marker when MSI+ and ultramutator CRCs were excluded from our main analysis based on 
gene panels (Table 1). We used our extended QUASAR2 and Australian cohorts and derived 
TP53 status from either NGS or Sanger sequencing. Within the MSI- CRC set (N=991), tumours 
with BRAF and TP53 mutations had a particularly poor prognosis (HR=3·08, 95%CI=1·88-5·03, 
P=7·12x10-6; Supp. Table 21; Figure 3), with a suggestive, but non-significant, interaction 
between these markers (HR=2·21, P=0·058), but no evidence of interaction between TP53 and 
KRAS (HR=1·13, P=0·62). Overall, therefore, we convincingly detected only independent 
prognostic effects of these three driver genes. 
 
 
DISCUSSION 
 
The use of prognostic molecular markers in the management of solid tumours is still not 
widespread. In part, this reflects a lack of validated markers and in part, differences between 
studies that have led to inconsistency in the recommended markers to use and their 
estimated effect sizes. For CRC, whilst several relatively large studies have assessed molecular 
indicators of CRC prognosis, most have been restricted to a handful of markers. In this study, 
we have used overlapping cancer gene mutation panels to analyse a high quality clinical trial 
of CRCs treated with curative intent and a validation cohort. In multivariable analysis 
incorporating known clinico-pathological prognostic factors, we have shown that low overall 
mutation burden and mutations in KRAS, BRAF and TP53 are independently associated with 
poorer RFS from CRC treated with curative intent. All these findings were also present in our 
Australian validation set, even though the patients in that study were from a community-
based collection rather than a clinical trial. The fact that we found no molecular marker of 
bevacizumab response in QUASAR2 or chemotherapy response in the Australian cohorts 
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(details not shown) suggested that the markers we have found are prognostic, although 
formally demonstrating this is difficult given that most of our patients received 5FU-based 
chemotherapy.  
 
The complexity of associations between mutations and CRC prognosis is arguably reflected in 
the generally stronger associations of markers in multivariable than univariable analyses. 
Furthermore, MSI was generally not prognostic in these analyses, because its effects were 
captured by mutation burden (somatic single nucleotide variants and small indels): however, 
mutation burden not only strongly co-varied with MSI and POLE, but also provided prognostic 
information in MSI- CRCs. Although high mutation burden has been associated with good CRC 
prognosis in the context of MSI and POLE proofreading deficiency12, this has not previously 
been shown for CRCs without those forms of genomic instability. Similar data from other 
tumour types are limited19-21, although in other cancers with generally high mutation burdens 
but without specific forms of genomic instability, such as lung carcinoma and melanoma, 
mutation burden has predicted response to immune checkpoint inhibitors22,23. It remains 
possible in our study that undetected hyper/ultramutator cancers contributed to the 
mutation burden association, although the frequencies of MSI and POLE mutations that we 
found were typical of other studies12 and we found a monotonic relationship between 
mutation burden quartile and RFS in our data. A further potential cause of the mutation 
burden association was non-excluded deamination artefacts if they happened to be 
associated with an unknown factor correlated with good prognosis; however, we made 
strenuous efforts to exclude those artefacts, no plausible explanatory causes such as tumour 
age were detectable within QUASAR2 (details not shown), and the Australian validation 
cohort was from fresh frozen tissue which is unlikely to have deamination. We note that the 
new observed association with mutation burden is sufficiently strong that even a modestly 
sized gene panel can pick it up, as it may be representative of mutation burden in the exome24. 
The underlying reason for the association between mutation burden and prognosis remains 
unclear, although anti-tumour immune responses are evidently the prime candidate19-21.  
 
The interplay between KRAS, BRAF and TP53 mutations, MSI and mutation burden in our data 
set is intriguing. These mutations co-vary strongly (Supp. Table 12), and are additionally 
associated with other molecular variables. Deciphering primary associations is therefore 
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extremely challenging. Nevertheless, our study strongly supports the reported poor prognosis 
of MSI- CRCs with KRAS or BRAF mutations5-10 compared with MSI- CRCs wildtype for these 
genes and unselected MSI+ CRCs; in addition, we found that KRAS or BRAF mutation may be 
associated with improved prognosis in MSI+ CRCs. TP53 has not previously been consistently 
reported as a prognostic marker for CRC in the curative setting, but very few large studies 
have undertaken a sufficiently comprehensive molecular analysis to include KRAS, BRAF, TP53 
and MSI. Notably, addition of these four prognostic markers improved outcome prediction 
compared with current clinical guidelines based on MSI. 
 
The strengths of our study are multiple potential biomarkers screened in a large, high quality 
clinical trial and a comparable, community-based cohort. We have very carefully performed 
quality control analysis to derive high-quality mutation calls. For mutation burden, the study 
is arguably limited by the size of the gene panels used, and a larger panel or exome/genome 
sequencing might detect even stronger associations with prognosis. In addition, the lower 
numbers of stage II patients in the sample set means that the utility of our model in such 
patients remains formally unproven. Moreover, we cannot  formally distinguish between the 
model being prognostic, or predictive for 5FU response. Another potential weakness is the 
different treatment regimens used in each cohort, although regimen was incorporated as a 
co-variable into the analyses. Finally, our study may have sub-optimal power to draw firm 
conclusions about outcomes in small patient groups or sub-groups, such as those with 
combinations of several molecular variables.  
 
Advances in molecular testing hold considerable promise for the delivery of precision cancer 
medicine, but their clinical use to date has largely been limited to the analysis of small 
numbers of actionable variants. In CRC, these include KRAS and NRAS mutation testing for 
prediction of resistance to anti-EGFR therapies25, or MSI, which identifies stage II tumours 
with excellent prognosis26 and stage IV tumours likely to respond to immune checkpoint 
inhibition27. Our findings show that the use of even a modest-sized gene panel can provide 
clinically useful information beyond individual driver mutations. In particular, tumour 
mutation burden displaced MSI/POLE as a marker of prognosis in multivariable analysis, thus 
extending the group of good-prognosis CRCs to include those with high mutation burden in 
the absence of a specific underlying mutator phenotype. While we were unable to test 
15 
 
whether mutational load is predictive for immunotherapy response in CRC, this correlation is 
well documented in other tumour types, including melanoma, lung and ovarian cancers28. 
Accordingly, our results suggest that the use of tumour mutation burden as a prognostic and 
predictive marker in CRC is worthy of further exploration, beyond tumours with MSI or POLE 
mutation. It is likely that other genome-wide molecular phenotypes, such as mutational 
signatures29, will come to play a role in cancer management in the future. 
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Table 1. Associations between clinico-pathological-molecular variables and relapse-free survival. 
Cox proportional hazards analysis was performed. The “univariable” analyses are adjusted by T stage, N stage and treatment arm (or 2 of these 
if the adjustment variable itself is being assessed). Multivariable analysis is based on all variables shown. Mutation burden is derived here from 
coding mutations , since these are most likely to be functionally relevant, but similar results are obtained when other somatic variants are also 
included (Supp. Figure 11). POLE proofreading mutation is not shown as a prognostic variable owing to the low frequency of those cancers 
(Supp. Table 11). 
  
(a) QUASAR2. N=511 (all cases, univariable and multivariable); N=443 (MSI-/Non-pathogenic POLE).  
 
 All cases univariable All cases multivariable MSI- & Non-pathogenic POLE multivariable 
 
HR 95% CI P HR 95% CI P HR 95% CI P 
KRAS mutation 1·48 1·07-2·05 0·018 1·99 1·37-2·91 3·44x10-4 2·25 1·51-3·35 6·07x10-5 
BRAF mutation 1·42 0·94-2·13 0·093 2·46 1·51-4·03 3·31x10-4 2·88 1·70-4·85 7·50x10-5 
TP53 mutation 1·53 1·08-2·18 0·018 1·63 1·12-2·38 0·011 1·61 1·09-2·38 0·025 
GNAS mutation 2·19 0·89-5·35 0·087 2·76 1·08-7·04 0·034 4·00 1·42-11.3 0·009 
Mutation burden (quartiles) 0·87 0·75-1·00 0·055 0·81 0·68-0·96 0·014 0·85 0·73-1·00 0·051 
MSI 0·73 0·42-1·28 0·271 1·12 0·57-2·19 0·75 -   
Chemotherapy (bevcap vs cap) 1·37 0·98-1·92 0·065 1·43 1·02-2·00 0·039 1·55 1·09-2·22 0·015 
T4 v T123 2·11 1·52-2·94 8·59x10-6 2·10 1·50-2·93 1·36x10-5 2·29 1·61-3·25 3·66x10-6 
N+ v N0 1·80 1·22-2·63 0·003 1·85 1·25-2·73 0·002 2·03 1·33-3·09 0·001 
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(b) Australian. N=296 (all cases without missing data, univariable); N=253 (all cases, multivariable); N=209 (MSI-/Non-pathogenic POLE). Note 
that BRAF was only tested for the common V600E variant and that GNAS was not tested. 
 
 
All cases univariable All cases multivariable MSI- & Non-pathogenic POLE multivariable 
HR 95%CI P HR 95%CI P HR 95%CI P 
KRAS mutation 1·31 0·92-1·87 0·136 1·51 0·97-2·38 0·066 1·61 1·02-2·59 0·040 
BRAF mutation 0·91 0·52-1·64 0·780 2·18 1·08-4·56 0·029 1·79 0·73-4·24 0·204 
TP53 mutation 1·19 0·83-1·71 0·334 1·82 1·12-2·73 0·014 1·81 1·09-2·82 0·020 
Mutation burden (quartiles) 0·72 0·62-0·85 8·62x10-5 0·78 0·63-0·95 0·014 0·82 0·64-0·93 0·008 
MSI 0·39 0·18-0·71 0·003 0·62 0·24-1·44 0·247 - -  - 
Chemotherapy (yes vs no) 1·01 0·71-1·44 0·946 0·60 0·34-0·91 0·019 0·51 0·18-0·90 0·018 
Radiotherapy (yes vs no) 1·21 0·50-3·02 0·653 1·33 0·53-3·32 0·546 1·29 0·51-3·20 0·603 
T4 v T123 2·19 1·54-3·22 2·01x10-5 2·38 1·57-3·75 6·34x10-5 2·67 1·73-4·21 1·62x10-5 
N+ v N0 1·4 0·97-2·08 0·070 1·21 0·71-2·04 0·493 1·19 0·66-2·05 0·597 
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(c) Combined 
For this analysis, N=807 (all cases without missing data, univariable); N=764 (all cases, multivariable); N=652 (MSI-/Non-pathogenic POLE). 
Mutation burden quartile was derived separately for the QUASAR2 and Australian cohorts owing to the different content of the two panels. 
Note that the cohort/treatment variables are categorical. 
 
 
All cases univariable All cases multivariable MSI- & Non-pathogenic POLE multivariable 
HR 95%CI P HR 95%CI P HR 95%CI P 
KRAS mutation 1·40 1·10-1·78 0·006 1·74 1·31-2·29 1·21x10-4 1·88 1·40-2·51 2·11x10-5 
BRAF mutation 1·23 0·88-1·72 0·231 2·21 1·47-3·29 1·02x10-4 2·32 1·50-3·58 1·49x10-4 
TP53 mutation 1·30 1·01-1·67 0·039 1·65 1·24-2·19 4·67x10-4 1·68 1·24-2·26 0·001 
Mutation burden (quartiles) 0·82 0·74-0·92 5·1x10-4 0·8 0·70-0·91 0·001 0·84 0·74-0·94 0·004 
MSI 0·58 0·38-0·89 0·012 0·8 0·46-1·35 0·399 - - - 
Cohort/treatment Q2 cap Ref.   Ref.   Ref.   
Cohort/treatment Q2 bev+cap 1·45 1·04-2·03 0·029 1·44 1·02-2·01 0·034 1·53 1·07-2·18 0·019 
Cohort/treatment Australia no chemo 2·04 1·4-2·98 2·2x10-4 3·48 2·28-5·30 7·04x10-9 4·05 2·58-6·34 9·96x10-10 
Cohort/treatment Australia chemo 2·06 1·45-2·93 5·61x10-6 1·75 1·18-2·58 0·005 1·88 1·25-2·83 0·002 
Radiotherapy (yes vs no) 1·56 0·64-3·78 0·326 1·37 0·54-3·41 0·503 1·3 0·51-3·24 0·579 
T4 v T123 1·81 1·42-2·29 1·30x10-6 2·19 1·68-2·83 3·03x10-9 2·36 1·80-3·09 4·38x10-10 
N+ v N0 1·45 1·11-1·89 0·006 1·63 1·21-2·20 0·001 1·68 1·21-2·30 0·002 
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Table 2. Prognosis associated with sub-groups by KRAS mutation, V600E BRAF mutation 
and MSI in all cohorts (N=1,732).  
P for interaction between MSI and BRAF and KRAS is 0·003 and 0·023 respectively.  Results 
are from multivariable analysis adjusted by cohort arms as shown in Table 1(c).  Six patients 
in very rare subgroups are not shown. 
 
All cohorts (N=1,732) HR 95%CI P 
KRASwt/BRAFwt/MSI- Ref.   
KRASmut/BRAFwt/MSI- 1·35 1·11-1·64 0·003 
KRASwt/BRAFmut/MSI- 2·02 1·47-2·76 1·20x10-5 
KRASwt/BRAFwt/MSI+ 0·90 0·56-1·45 0·670 
KRASmut/BRAFwt/MSI+ 0·28 0·09-0·89 0·028 
KRASwt/BRAFmut/MSI+ 0·55 0·35-0·90 0·017 
T4 v T123 2·26 1·88-2·71 3·32x10-18 
N+ v N0 2·07 1·65-2·59 2·62x10-10 
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FIGURE LEGENDS 
 
Figure 1. Relapse-free survival in combined QUASAR2 and Australian cohorts by mutation 
burden from gene panel analysis (N=672). Burden data are shown by quartile (highest burden 
in Q4). Cancers that were MSI+ or carried pathogenic POLE mutations were excluded. Cox 
proportional hazards model results are also shown for univariable and multivariable analyses 
with Q1-4 as a continuous variable and other co-variables as per Table 1c. Note that the 
numbers in each quartile are not equal owing to ties in mutation burden.  
Figure 2. Relapse-free survival by combinations of MSI and mutations in KRAS and BRAF in 
the combined extended QUASAR2 and Australian cohorts. Cancers that carried pathogenic 
POLE mutations were excluded. 
Figure 3. Relapse-free survival by combinations of mutations in KRAS, BRAF and TP53 in the 
combined extended QUASAR2 and Australian cohorts. Cancers that were MSI+ or carried 
pathogenic POLE mutations were excluded.  
 
 
